Life Edit Therapeutics
A gene editing platform with a large collection of proprietary RNA-guided nucleases and base editors for developing curative cell and gene therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Life Edit Therapeutics, a subsidiary of ElevateBio, operates in the biotechnology sector with a focus on next-generation gene editing technologies. The company is developing a portfolio of RNA-guided nucleases and base editors, which it claims is one of the largest and most diverse in the world. Its discovery platform is built upon a proprietary collection of non-pathogenic organisms, enabling the development of novel editing systems.
The company's business model involves both in-house therapeutic development and strategic collaborations. It is advancing its own pipeline of therapies targeting genetic diseases, while also partnering with other biotechnology firms, such as Moderna, to co-develop new treatments. This dual approach allows the company to pursue its own therapeutic candidates while also generating revenue and validating its platform through partnerships.
Life Edit Therapeutics serves the pharmaceutical and biotechnology industries by providing access to its gene editing tools and expertise. The company's market is the rapidly growing field of cell and gene therapy, with a focus on creating curative treatments for previously incurable diseases. Its revenue is generated through milestones and royalties from its collaborations, as well as the potential future commercialization of its proprietary therapeutic products.
Keywords: gene editing, therapeutics, CRISPR, base editing, cell therapy, gene therapy, biotechnology, genetic diseases, drug development, nucleases